National Cannabis Industry Association’s Response to the U.S. Food and Drug Administration’s Request for Public Comments on Scientific Data and Information About Products Containing Cannabis or Cannabis-Derived Compounds

On behalf of the National Cannabis Industry Association (NCIA), and in response to the U.S. Food and
Drug Administration (FDA) request for comments on Scientific Data and Information About Products
Containing Cannabis or Cannabis-Derived Compounds, published in the April 3, 2019 edition of the
Federal Register, we hereby submit public comments.

Given the substantial interest in this topic and the need for regulations and standardization throughout
the industry, NCIA and this coalition are providing specific insight into all facets the FDA would like to
examine, including health and safety risks, manufacturing and product quality, and marketing, labeling,
and sales.

Hemp-derived CBD is in high demand by consumers, and the industry is eagerly awaiting the FDA’s
regulatory framework for these products. Our industry coalition firmly believes that by working in
partnership with the FDA to inform rulemaking, we can develop an appropriate regulatory framework to
ensure the safety and efficacy of these important products.